Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: A retrospective cohort study

Mayo Clinic Proceedings

Volumn 84, Issue 12, 2009, Pages 1073-1078

  Bauer, Seth R ^a   Ou, Narith N ^b   Dreesman, Benjamin J ^b   Armon, Jeffrey J ^b   Anderson, Jan A ^b   Cha, Stephen S ^b   Oyen, Lance J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; THROMBOPLASTIN; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HUMAN; LOADING DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PARTIAL THROMBOPLASTIN TIME; PROSTHETIC VALVE DYSFUNCTION; RETROSPECTIVE STUDY; THORAX PAIN; TREATMENT INDICATION; UNIVERSITY HOSPITAL;

EID: 72949098312     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0220     Document Type: Article

References (21)

1. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med. 1993;119(9):874-881.
2. Schaefer DC, Hufnagle J, Williams L. Rapid heparin anticoagulation: use of a weight-based nomogram. Am Fam Physician. 1996;54(8):2517-2521.
3. Spruill WJ, Wade WE, Huckaby WG, Leslie RB. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm. 2001;58(22):2143-2146.
4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) [published correction appears in Circulation. 2005;111(15):2013]. Circulation. 2004;110(5):588-636.
5. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). [published correction appears in Circulation. 2008;117(9):e180]. Circulation. 2007 Aug 14;116(7):e-48-e304. Epub 2007 Aug 6.
6. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm. 1998;55(2):159-162.
7. Oyen LJ, Nishimura RA, Ou NN, Armon JJ, Zhou M. Effectiveness of a computerized system for intravenous heparin administration: using information technology to improve patient care and patient safety. Am Heart Hosp J. 2005;3(2):75-81.
8. Wilson JW, Oyen LJ, Ou NN, et al. Hospital rules-based system: the next generation of medical informatics for patient safety. Am J Health Syst Pharm. 2005;62(5):499-505.
9. World Health Organization. Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452.
10. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM; ESSENCE and TIMI 11B studies. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146(1):33-41.
11. Kershaw B, White RH, Mungall D, Van Houten J, Brettfeld S. Computer-assisted dosing of heparin: management with a pharmacy-based anticoagulation service. Arch Intern Med. 1994;154(9):1005-1011.
12. Holliday DM, Watling SM, Yanos J. Heparin dosing in the morbidly obese patient [letter]. Ann Pharmacother. 1994;28(9):1110-1111.
13. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3)(suppl):287S- 310S.
14. The urokinase pulmonary embolism trial. A national cooperative study. Circulation. 1973;47(2 suppl):II1-II108.
15. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J; Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003 Jun 17;107(23):2884-2888. Epub 2003 Jun 9.
16. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93(5):870-878.
17. Norman CS, Provan JL. Control and complications of intermittent heparin therapy. Surg Gynecol Obstet. 1977;145(3):338-342.
18. Wilson JE III, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med. 1981;70(4):808-816.
19. Landefeld CS, McGuire E III, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1990;89(5):569-578.
20. Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton K. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis. 2008 Nov-Dec;4(6):748-753. Epub 2008 Jun 30.
21. Badawi O, Oyen LJ, Haines ST. Dosing of unfractionated heparin in acute coronary syndromes. Pharmacotherapy. 2004;24(12):1681-1691.